PFIZER INC Annual Report, Year Ended Dec 31, 2003

Pfizer Inc.'s 2003 10-K filing indicates a company actively engaged in its core pharmaceutical business, with diversified segments including Consumer Healthcare and Animal Health. The report emphasizes significant investment in Research and Product Development, a critical driver for future growth and maintaining a competitive edge in the pharmaceutical landscape. Pfizer operates globally, with substantial international operations contributing to its overall revenue and market presence. The company highlights its strong patent portfolio and intellectual property rights as key assets, though it also acknowledges the inherent risks associated with competition, regulatory environments, and potential government price constraints. Investors should note Pfizer's proactive approach to managing its business through its various segments and its commitment to innovation through R&D. The company's extensive marketing efforts and global reach suggest a robust strategy for product penetration. However, the presence of numerous competitors and the evolving landscape of government regulation and pricing policies represent important factors that could influence future financial performance and require ongoing monitoring by shareholders.